Pharma BD Deal Intelligence

Ipsen S.A. / Marengo Therapeutics, Inc.

2024 · Licensing/Option · $1.2B · Complete

Ipsen and Marengo Therapeutics announced a second strategic partnership expanding their 2022 oncology collaboration to Marengo's TriSTAR precision T cell engager platform plus up to two additional early-stage assets, focused on 'cold' tumors. Marengo receives an undisclosed upfront and payments of up to $1.2 billion in total if all milestones are met, plus tiered sales royalties; Ipsen assumes responsibility for all activities after development candidate nomination.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals  ·  Ipsen S.A. deals